Pyoderma gangrenosum
Pyoderma gangrenosum ni ugonjwa adimu wa ngozi unaosababisha uvimbe, ambapo pustula au vinundu vyenye uchungu huwa vidonda vinavyokua polepole. Pyoderma gangrenosum siambukizwa. Matibabu yanaweza kujumuisha corticosteroids, ciclosporin, au dawa za kingamwili (monoclonal). Ingawa inaweza kuathiri watu wa umri wowote, inawadhuru zaidi watu wa miaka ya 40 hadi 50.
☆ AI Dermatology — Free Service
Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
Kwenye mguu wa mtu aliye na colitis ya kidonda.
relevance score : -100.0%
ReferencesPyoderma gangrenosum ni hali adimu ya ngozi inayosababisha vidonda vyenye uchungu na ukungu wa rangi nyekundu au zambarau. Inachukuliwa kama ugonjwa wa uchochezi na ni sehemu ya kundi linaloitwa neutrophilic dermatoses. Sababu ya Pyoderma gangrenosum ni mchanganyiko, ikihusisha matatizo ya kinga ya asili na yanayoweza kubadilika kwa watu wenye hatari ya kuathiriwa na vinasaba. Hivi majuzi, watafiti wamezingatia follicule ya nywele kama sehemu ya mwanzo wa ugonjwa huo.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum ni hali adimu ya ngozi inayosababisha vidonda vya maumivu sana. Ingawa hatuelewi kikamilifu sababu yake, tunajua inahusisha kuongezeka kwa shughuli za seli fulani za kinga. Kutibu ugonjwa bado si rahisi. Tuna dawa mbalimbali zinazokandamiza mfumo wa kinga au kurekebisha shughuli zake. Kando na hayo, tunazingatia pia kutibu majeraha na kudhibiti maumivu. Corticosteroids na cyclosporine mara nyingi ni chaguo la kwanza kwa matibabu, lakini hivi majuzi, kumekuwa na utafiti zaidi kuhusu kutumia matibabu ya kibiolojia kama vile vizuizi vya TNF-α. Matibabu haya yanayozidi kupendelewa, hasa kwa wagonjwa walio na hali zingine za uchochezi, na yanatumiwa mapema katika mchakato wa ugonjwa.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
